Abstract
A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3-4 |
| Number of pages | 2 |
| Journal | ACS Chemical Neuroscience |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 18 2012 |
| Externally published | Yes |
Keywords
- Alzheimer's disease
- Aβ-peptides
- GSI
- γ-secretase inhibitors
ASJC Scopus subject areas
- Biochemistry
- Physiology
- Cognitive Neuroscience
- Cell Biology